|Year : 2019 | Volume
| Issue : 2 | Page : 57-63
The global prevalence of thrombocytopenia among pregnant women: A systematic review and meta-analysis
, Zoleykha Asgarlou2
, Saber Azami-Aghdash3
, Sepideh Gareh Sheyklo4
, Nikta Tavananezhad5
, Ahmad Moosavi6 1 Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran
2 Department of Midwifery, School of Nursing and Midwifery, Zanjan University of Medical Sciences, Zanjan, Iran
3 Tabriz Health Services Management Research Center, Health Management and Safety Promotion Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
4 Department of Obstetrics and Gynecology, Dezful University of Medical Sciences, Dezful, Iran
5 Department of Midwifery, Faculty of Nursing and Midwifery, Islamic Azad University, Sanandaj, Iran
6 Department of Health and Community Medicine, Dezful University of Medical Sciences, Dezful, Iran
|Date of Web Publication||30-Apr-2019|
Department of Health and Community Medicine, Dezful University of Medical Sciences, Dezful
Source of Support: None, Conflict of Interest: None
Background: Thrombocytopenia (TCP) is a common disorder during pregnancy. Its prevalence among pregnant women is four times greater than nonpregnant women. Objectives: This study aimed at determining the global prevalence of TCP among pregnant women. Methods: This systematic review and meta-analysis was conducted in 2018. The PubMed, Scopus, Google Scholar, Magiran, and IranMedex databases were searched using the following key words: “TCP,” “pregnancy,” “pregnant,” “pregnant women,” “gestational,” and “platelets.” The titles and the abstracts of the retrieved studies were screened to identify potentially relevant studies. Articles were included if they were the reports of original researches, included data on the prevalence of TCP among pregnant women, were in English or Persian, and had been published from January 1, 2000 to September 1, 2018. Eligible studies were appraised using the Strengthening the Reporting of Observational Studies in Epidemiology checklist. Finally, a data collection form was used to extract data. The overall prevalence of TCP among pregnant women was estimated using meta-analysis and the Comprehensive Meta-Analysis Software. Heterogeneity was evaluated through the Chi-square test and the I2 statistic, and funnel plot was used to evaluate the possibility of publication bias. Results: Among 1592 studies retrieved during literature search, sixteen were included in meta-analysis. The overall prevalence of TCP among pregnant women based on the random effects model was 8.4% (95% confidence interval: 6.9%–10.1%). The lowest TCP prevalence was 4.3% in Taiwan, while the highest prevalence was 15.3% in Ghana. Gestational TCP was the most common cause of TCP among pregnant women. Conclusion: With a global prevalence of 8.4%, TCP in pregnancy affects around one-tenth of pregnant women in the world. Thus, timely diagnostic, preventive, and therapeutic measures are needed to effectively manage TCP in pregnancy.
Keywords: Iran, Meta-analysis, Pregnancy, Prevalence, Thrombocytopenia
|How to cite this article:|
Mohseni M, Asgarlou Z, Azami-Aghdash S, Sheyklo SG, Tavananezhad N, Moosavi A. The global prevalence of thrombocytopenia among pregnant women: A systematic review and meta-analysis. Nurs Midwifery Stud 2019;8:57-63
|How to cite this URL:|
Mohseni M, Asgarlou Z, Azami-Aghdash S, Sheyklo SG, Tavananezhad N, Moosavi A. The global prevalence of thrombocytopenia among pregnant women: A systematic review and meta-analysis. Nurs Midwifery Stud [serial online] 2019 [cited 2021 Mar 9];8:57-63. Available from: https://www.nmsjournal.com/text.asp?2019/8/2/57/257439
| Introduction|| |
Thrombocytopenia (TCP) refers to abnormally low levels of circulating platelets. It occurs in about 6%–15% of all pregnant women. Gestational TCP, the most common cause of TCP during pregnancy, accounts for about 75% of all cases of TCP among pregnant women.,, TCP is four times more prevalent among pregnant women than nonpregnant women.,
Platelets play significant role in hemostasis. Thus, severe TCP, i.e., a platelet count of <100,000/μl, can be associated with increased risk for serious bleeding, Similarly, severe TCP in pregnancy can cause serious bleeding and subsequently maternal and fetal complications.
There are several causes for TCP in pregnancy, including gestational TCP, acute fatty liver of pregnancy, preeclampsia, and hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome.,
Most pregnant women with TCP are healthy and asymptomatic, have no history of TCP, and are incidentally diagnosed with TCP during blood testing. This kind of TCP is called incidental or gestational TCP and usually has no significant effects on pregnancy, labor, delivery, and the newborn.
The results of previous studies into the prevalence of TCP in pregnancy do not provide a comprehensive framework for clinical decision-making because they were conducted in small populations and samples. A strategy to increase the usefulness and the applicability of the findings of these studies is to systematically analyze them.
The present study was conducted to systematically review the previous studies into the prevalence of TCP in pregnancy and thereby, determine the global prevalence of TCP among pregnant women.
| Methods|| |
This systematic review and meta-analysis was conducted in 2018 based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement.
Data were collected through searching the existing literature. Online databases, namely PubMed, Scopus, Google Scholar, Magiran, and IranMedex were searched using the following key words: “TCP,” “pregnancy,” “pregnant,” “pregnant women,” “gestational,” and “platelets.” Boolean operators, namely “AND,” “OR,” and “NOT,” were used to narrow or broaden search results. Search results were exported to the EndNote X5 (Thomson Reuters, New York, NY, USA) to assess the titles and the abstracts of the studies and to identify duplicate records. Moreover, the reference lists of eligible articles were also hand searched for additional studies.
Study selection and quality appraisal
Two reviewers (M.M and AM) independently screened the titles and the abstracts of the articles to identify potentially relevant studies. Then, they independently performed eligibility assessment. Any disagreement between them was resolved based on the comments of a third reviewer (S.AA). Articles were included if they were the reports of original researches, included data on the prevalence of TCP among pregnant women, were in English or Persian, and had been published from January 1, 2000 to September 1, 2018. Interventional and qualitative studies, case reports, proceedings, and studies into the prevalence of TCP among women with serious health conditions (such as acquired immunodeficiency syndrome) were not included. Two reviewers (S.G and ZA) independently appraised the retrieved studies using the Strengthening the Reporting of Observational Studies in Epidemiology checklist., This checklist contains 22 items. The articles that did not passed at least half of items were excluded from the study.
A standard data collection form was used to extract data on the following items from the retrieved articles: author, publication year, country, study design, sample size, TCP prevalence, and conclusion.
The overall prevalence of TCP in pregnant women was estimated by performing meta-analysis using the Comprehensive Meta-Analysis software (version 2, Biostat, Inc., Englewood, NJ, USA). Forest plots with 95% confidence interval (95% CI) were used to report the results. The heterogeneity of the studies was evaluated through the Chi-square test and the I2 statistic (P > 0.05 or I2 > 50%). Publication bias was investigated visually using funnel plots and statistically using Egger's test. Graphs were drawn using the Microsoft Office Excel 2010.
| Results|| |
Of 1592 studies identified in the initial search, 1205 were removed due to duplicates. Furthermore, in the title and abstract screening, 355 studies, and in the full-text screening, 16 cases were excluded. In total, sixteen studies on 36,499 pregnant women with TCP were included [Figure 1]. Studies had been conducted between 2001 and 2018 in India (five studies), Iran (three studies), Pakistan, Ethiopia, Sudan, Taiwan, Ghana, Spain, Iraq, and Cameroon (one in each country). [Table 1] shows the characteristics of these sixteen studies.
The lowest TCP prevalence was 4.3% in Taiwan and 5.2% in Iran, while the highest TCP prevalence was 15.3% in Ghana and 13.4% in Sudan.
The meta-analysis of these sixteen studies showed that the overall prevalence of TCP based on the random effects model was 8.4% (95% confidence interval [CI]: 6.9%–10.1%). For TCP prevalence in each study, 95% CI was drawn in the horizontal line format [Q = 267.9, df = 15, P < 0.05, I2 = 94.4; [Figure 2]. Due to high heterogeneity of results, sensitivity analysis was done with excluding Bai et al., Vyas et al., Lin et al., and Yazdani et al. The results showed that after sensitivity analysis, heterogeneity improved considerably (Q = 31, df = 12, P < 0. 05, I2 = 62). After this change, the overall prevalence of TCP based on the random effect model was 9.2%. Funnel plot was used to evaluate publication bias. Its results showed that there was a possibility of publication bias among the studies [Figure 3]. There was statistically significant evidence of publication bias for Begg and Egger's test (P < 0.05). Subgroup analysis was done by country [Table 2] and showed a homogenous result in India (Q = 1.8, df = 4, P = 0.75, I2 = 0.00).
| Discussion|| |
This study aimed to determine the global prevalence of TCP among pregnant women. Findings revealed that the global prevalence of TCP in pregnancy was 8.4%, and the most common cause of TCP in pregnancy was gestational TCP. The lowest and the highest prevalence rates of TCP were 4.3% and 15.3%, respectively.
During our literature search, we found studies into the prevalence of TCP among pregnant women with serious health conditions. For instance, a study on pregnant women with acquired immunodeficiency syndrome who were not under treatment reported a TCP prevalence of 5.3%. Another study on pregnant women with hypertensive disease of pregnancy also found that 23.5% of them had TCP. Moreover, TCP prevalence among women who used cocaine was reported to be 6.7%. However, there is a paucity of studies into the effects of different health conditions on TCP. Thus, further studies, particularly case–control studies, are needed to evaluate how different health conditions affect TCP in pregnancy.
The most common cause of TCP in the reviewed studies was gestational TCP so that a study in Iran reported it as the leading cause of 95% of TCPs among pregnant women. This rate in other studies was 85%, 81%, 92.9%, 73.8%, 70%, and 64.2%. The pathophysiology of gestational TCP is unknown; however, it is assumed that its cause may be the high consumption of platelets during pregnancy or increased plasma volume due to pregnancy. Gestational pregnancy is mild, benign, and asymptomatic, with no previous history of TCP, except in previous pregnancies. It usually happens at the end of pregnancy, is not associated with fetal TCP, and spontaneously improves after delivery. Of course, the differentiation between benign TCP and other types of TCP in pregnancy such as HELLP and preeclampsia is essential to avoid unnecessary interventions for gestational TCP and to take timely measures to manage pathologic TCPs.
Some studies showed that TCP in pregnancy is associated with maternal and neonatal morbidity and mortality. For instance, several studies reported that 0.30%–13.20% of the neonates of thrombocytopenic women needed admission to neonatal intensive care unit.,, Another study on eight cases of pathologic TCP in pregnancy reported that one neonate developed cerebral hemorrhage. Therefore, careful and continuous monitoring of high risk thrombocytopenic women is needed to determine TCP etiology and take timely interventions to prevent probable complications.
Our study also revealed that there are limited studies in the area of TCP prevalence in pregnancy. Therefore, further studies are recommended to determine TCP prevalence in different areas of the world and evaluate the effects of preventive and therapeutic interventions on TCP-related outcomes among pregnant women. Moreover, routine screening and follow-up programs are needed to identify pregnant women with TCP and provide them with the necessary interventions to prevent potential fetal and maternal complications. The limitations of the present study were our limited access to some databases as well as the inclusion of only English and Persian studies. Another limitation was high possibility of publication bias and heterogeneity in results, and readers should pay attention to this issue.
| Conclusion|| |
The global prevalence of TCP among pregnant women is 8.4%. In other words, around one-tenth of pregnant women in the world suffer from TCP. This high rate highlights the importance of taking diagnostic, preventive, and therapeutic measures for the management of TCP in pregnancy.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Ruggeri M, Schiavotto C, Castaman G, Tosetto A, Rodeghiero F. Gestational thrombocytopenia: A prospective study. Haematologica 1997;82:341-2.
Boehlen F, Unit H. Thrombocytopenia during pregnancy. Importance, diagnosis and management. Hämostaseologie 2006;26:72-4.
Keihanian S, Zakerihamidi M, Sadeghi F, Khalatbari J. Frequency of thrombocytopenia in pregnancy between pregnants who comes to health centers of Tonekabon in 2009. J Ardabil Univ Med Sci 2010;10:362-9.
Myers B. Diagnosis and management of maternal thrombocytopenia in pregnancy. Br J Haematol 2012;158:3-15.
Olayemi E, Akuffo FW. Gestational thrombocytopenia among pregnant Ghanaian women. Pan Afr Med J 2012;12:34.
Ciobanu AM, Colibaba S, Cimpoca B, Peltecu G, Panaitescu AM. Thrombocytopenia in pregnancy. Maedica (Buchar) 2016;11:55-60.
Onyangunga OA, Moodley J. Managing pregnancy with HIV, HELLP syndrome and low platelets. Best Pract Res Clin Obstet Gynaecol 2012;26:133-47.
Jodkowska A, Martynowicz H, Kaczmarek-Wdowiak B, Mazur G. Thrombocytopenia in pregnancy – Pathogenesis and diagnostic approach. Postepy Hig Med Dosw (Online) 2015;69:1215-21.
Nisha S, Amita D, Uma S, Tripathi AK, Pushplata S. Prevalence and characterization of thrombocytopenia in pregnancy in Indian women. Indian J Hematol Blood Transfus 2012;28:77-81.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al.
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Ann Intern Med 2009;151:W65-94.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al.
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9.
Mohseni M, Alikhani M, Tourani S, Azami-Aghdash S, Royani S, Moradi-Joo M, et al.
Rate and causes of discharge against medical advice in Iranian hospitals: A systematic review and meta-analysis. Iran J Public Health 2015;44:902-12.
Gallin JI, Ognibene FP. Principles and Practice of Clinical Research, 3rd
ed., London: Academic Press; 2012.
Lin YH, Lo LM, Hsieh CC, Chiu TH, Hsieh TT, Hung TH, et al.
Perinatal outcome in normal pregnant women with incidental thrombocytopenia at delivery. Taiwan J Obstet Gynecol 2013;52:347-50.
Yazdani S, Bouzari Z, Sedaghat S, Samakoosh MA, Farajnezhad K. Incidence of thrombocytopenia in pregnancy and associated factors. J Mazandaran Univ Med Sci 2012;22:58-64.
Mubarak N, Gasim GI, Khalafalla KE, Ali NI, Adam I. Helicobacter pylori
, anemia, iron deficiency and thrombocytopenia among pregnant women at Khartoum, Sudan. Trans R Soc Trop Med Hyg 2014;108:380-4.
Bai P, Memon I, Ashfaq S, Sultan S, Irfan SM. prevalence and etiology of thrombocytopenia in pregnant women in Southern Pakistan. J Soc Obstet Gynaecol Pak 2018;8:15-9.
Vyas R, Shah S, Yadav P, Patel U. Comparative study of mild versus moderate to severe thrombocytopenia in third trimester of pregnancy in a tertiary care hospital. NHL J Med Sci 2014;3:8-11.
Sebitloane HM. Thrombocytopenia during pregnancy in women with HIV infection receiving no treatment. S Afr Med J 2016;106:210-3.
Habas E, Rayani A, Ganterie R. Thrombocytopenia in hypertensive disease of pregnancy. J Obstet Gynaecol India 2013;63:96-100.
Kain ZN, Mayes LC, Pakes J, Rosenbaum SH, Schottenfeld R. Thrombocytopenia in pregnant women who use cocaine. Am J Obstet Gynecol 1995;173:885-90.
Asrie F, Enawgaw B, Getaneh Z. Prevalence of thrombocytopenia among pregnant women attending antenatal care service at Gondar University teaching hospital in 2014, Northwest Ethiopia. J Blood Med 2017;8:61-6.
Das N, Das S. Prevalence and causes of thrombocytopenia in pregnant women from North-East India. Paripex Indian J Res 2017;6:42-4.
Chauhan V, Gupta A, Mahajan N, Vij A, Kumar R, Chadda A. Maternal and fetal outcome among pregnant women presenting with thrombocytopenia. Int J Reprod Contracept Obstet Gynecol 2017;5:2736-43.
Dwivedi P, Puri M, Nigam A, Agarwal K. Fetomaternal outcome in pregnancy with severe thrombocytopenia. Eur Rev Med Pharmacol Sci 2012;16:1563-6.
Epstein A, Wing DA, Ouzounian JG, Miller DA, Lee RH. Helicobacter pylori
and thrombocytopenia in the pregnant Hispanic population. J Matern Fetal Neonatal Med 2012;25:2588-90.
Shamoon RP, Muhammed NS, Jaff MS. Prevalence and etiological classification of thrombocytopenia among a group of pregnant women in Erbil city, Iraq. Turk J Haematol 2009;26:123-8.
Mbanya D, Tayou Tagny C, Takoeta E, Mbu R, Kaptue L. [Factors associated with thrombocytopenia among pregnant women in Cameroon]. Sante 2007;17:213-7.
Modarresnejad V, Motamedi B. Study of the prevalence of thrombocytopenia and factors affecting it in Kerman. Asrar 2001;9:4-10.
Giles C. The platelet count and mean platelet volume. Br J Haematol 1981;48:31-7.
Sainio S, Kekomäki R, Riikonen S, Teramo K. Maternal thrombocytopenia at term: A population-based study. Acta Obstet Gynecol Scand 2000;79:744-9.
Letsky EA, Greaves M. Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Maternal and neonatal haemostasis working party of the haemostasis and thrombosis task force of the British Society for Haematology. Br J Haematol 1996;95:21-6.
McCrae KR. Thrombocytopenia in pregnancy: Differential diagnosis, pathogenesis, and management. Blood Rev 2003;17:7-14.
Szkodny E, Sikora J, Bakon I, Zietek J. Pregnancy and delivery in women with thrombocytopenia. Ginekol Pol 2001;72:1296-9.
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2]